Exiqon to Shut Down California Lab After Reimbursement Issue Stymies Sale Talks

Despite the setback, Exiqon remains on track with its strategy of marketing its microRNA-based diagnostics in collaboration with partners, and expects to announce a deal before the end of the year, a company official said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.